AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

New therapeutic target for treating nonalcoholic steatohepatitis (NASH) and fatty liver disease

Summary: Rudolph L Leibel, M.D.

Technology Benefits: Provides a target for NASH therapeutic developmentProvides a target for dyslipidemia therapeutic developmentPatent information:N/ATech Ventures Reference: IR CU13175

Technology Application: Pharmaceutical activators of ILDR2 may reduce lipid accumulation in the liver to treat NASH patients.ILDR2 alters lipoprotein metabolism and may be used to treat dyslipidemia and atherosclerosis. Characterization of ILDR2 suggests a role in preservation of beta cell mass, and control of body weight.

Detailed Technology Description: Rudolph L Leibel, M.D.

*Abstract: None

*Inquiry: Ron KatzColumbia Technology VenturesTel: (212) 854-8444Email: TechTransfer@columbia.edu

*IR: CU13175

*Principal Investigator

*Publications: Watanabe K, Watson E, Cremona ML, Millings EJ, Lefkowitch JH, Fischer SG, LeDuc CA, Leibel RL. (2013) ILDR2: an endoplasmic reticulum resident molecule mediating hepatic lipid homeostasis. PLoS One. Vol 8(6):e67234.

Country/Region: USA

For more information, please click Here